TEA Changes, GRASE Basics Central To CHPA Monograph Comments
This article was originally published in The Tan Sheet
Executive Summary
CHPA suggests accelerating the introduction of additional monograph ingredients while hewing to the agency’s existing OTC Drug Review. The group also says “if FDA returns to the origins of the OTC Drug Review and examines the bases for its early success, the remaining monographs can be completed and updated.”
You may also be interested in...
J&J Suggests Targeting OTC Monograph With Public-Private Initiative
An FDA guidance provides the framework for J&J consumer business executives’ suggestions to improve the OTC drug review. A public-private partnership “is key to developing and delivering a comprehensive solution,” says Lynne Szczepaniak, regulatory affairs VP at J&J’s McNeil Consumer Healthcare subsidiary.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade
Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.